

A Phase 2 Study of CRD-4730 in CPVT

NCT06658899

Status	RECRUITING
Phase	Phase 2
Sponsor	Cardurion Pharmaceuticals, Inc.
Enrollment	12 participants

Key Eligibility Criteria

Inclusion (6)

- Each participant must meet all the following criteria to be enrolled in this study:
 - The participant is male or female, e18 years of age and of legal adult age in accordance with local requirements.
 - The participant has a confirmed CPVT diagnosis, based on genetic screening for a pathogenic ryanodine receptor (RYR2) mutation and a clinical phenotype consistent with CPVT at Screening. Previous CPVT genetic testing documented in medical history is acceptable if confirmed by the Investigator and documented in the study source records.
 - The participant can perform an EST during which frequent premature ventricular contractions (PVCs; e10 per minute), ventricular bigeminy, or higher-grade VA (equivalent to a VA score e2) are identified by the Investigator.
 - The participant has been on a stable dose of at least 1 antiarrhythmic medication (including beta blockers but not amiodarone) for 4 weeks prior to Screening, unless the participant has been unable to tolerate antiarrhythmic therapy previously.
- ... and 1 more (see full listing online)

Exclusion (12)

- Participants meeting any of the following criteria will be excluded from the study:
 - The participant has clinically significant structural heart disease, diagnosis of heart failure, or clinically significant coronary artery disease.
 - The participant has a clinically significant abnormal ECG not explained by the diagnosis of CPVT at Screening or clinically significant abnormal intervals, such as prolonged QT.
 - The participant has a history of a myocardial infarction, cerebrovascular accident, or transient ischemic attack within 3 months of Screening.
 - The participant undergoes implantable cardioverter-defibrillator (ICD) implantation or has sympathetic nerve denervation within 3 months of Screening.
- ... and 7 more (see full listing online)

Locations (9 total)

Cardurion Investigative Site, San Francisco, California, United States
Cardurion Investigative Site, Morrisville, North Carolina, United States
Cardurion Investigative Site, Houston, Texas, United States
... and 6 more locations